FDAnews
www.fdanews.com/articles/81561-medarex-and-massachusetts-biologic-laboratories-begin-cda-1-trial

MEDAREX AND MASSACHUSETTS BIOLOGIC LABORATORIES BEGIN CDA-1 TRIAL

October 11, 2005

Medarex and The Massachusetts Biologic Laboratories of the University of Massachusetts Medical School today announced the initiation of a randomized, placebo-controlled Phase II clinical trial of CDA-1 (also referred to as MDX-066), a novel fully human monoclonal antibody they developed to treat Clostridium difficile (C. difficile) Toxin A, for hospitalized patients diagnosed with C. difficile associated diarrhea (CDAD).

The single-dose clinical trial will be conducted at hospitals in Massachusetts and California and is expected to enroll up to 150 patients with CDAD. The study is designed to assess the safety and tolerability of CDA-1 when added to standard of care and to measure and compare the duration of CDAD after treatment, the length of hospital stay and recurrence of CDAD after treatment between the placebo and treatment arms.